8-K: Candel Therapeutics' CAN-2409 Meets Primary Endpoint in Phase 3 Prostate Cancer Trial, Showing Significant Improvement in Disease-Free Survival

Candel Therapeutics announced positive topline results from its Phase 3 trial of CAN-2409 in intermediate-to-high risk prostate cancer, demonstrating a statistically significant improvement in disease-free survival, while a Phase 2b trial in low-to-intermediate risk prostate cancer did not meet its primary endpoint.

Summary

• Candel Therapeutics announced positive topline data from its Phase 3 clinical trial evaluating CAN-2409 in patients with intermediate-to-high risk localized prostate cancer.
• The Phase 3 trial met its primary endpoint, showing a statistically significant improvement in disease-free survival (DFS) compared to the control arm.
• The study enrolled 745 patients and demonstrated a 14.5% relative improvement in DFS at 54 months for the CAN-2409 treatment arm.
• The treatment arm also showed a highly significant effect on prostate cancer-free survival with a p-value of 0.0046 and a hazard ratio of 0.6.
• A significant increase in the proportion of patients achieving a prostate-specific antigen (PSA) nadir of less than 0.2 ng/ml was observed in the treatment arm (67.1%) compared to the control arm (58.6%).
• CAN-2409 induced 80.4% pathological complete responses in the 2-year post-treatment biopsies compared to 63.6% in the control arm.
• The median follow-up time for the study was 50.3 months.
• The safety profile of CAN-2409 was consistent with previous studies, with common adverse events being mild to moderate flu-like symptoms.
• Candel intends to initiate discussions with the FDA regarding the regulatory pathway for CAN-2409 and anticipates submitting a biologics license application in the fourth quarter of 2026.
• The Phase 2b trial of CAN-2409 in low-to-intermediate risk prostate cancer did not meet its primary endpoint, although it showed numerical improvements that were not statistically significant.

Sentiment

Score: 8

Explanation: The document presents very positive results from the Phase 3 trial, indicating a significant advancement in prostate cancer treatment. However, the Phase 2b trial not meeting its primary endpoint tempers the overall sentiment slightly.

Positives

• The Phase 3 trial demonstrated a statistically significant improvement in disease-free survival for CAN-2409 in intermediate-to-high risk prostate cancer.
• The 14.5% relative improvement in DFS at 54 months is considered clinically meaningful.
• CAN-2409 showed a highly significant effect on prostate cancer-specific outcomes.
• The treatment resulted in a significant increase in patients achieving a PSA nadir of <0.2 ng/ml.
• CAN-2409 induced a high rate of pathological complete responses in post-treatment biopsies.
• The safety profile of CAN-2409 was consistent with previous studies, with no new safety signals identified.
• The study was conducted under a Special Protocol Assessment (SPA) with the FDA, which could facilitate regulatory approval.
• The company plans to submit a BLA in Q4 2026.

Negatives

• The Phase 2b trial of CAN-2409 in low-to-intermediate risk prostate cancer did not meet its primary endpoint.
• While the Phase 2b trial showed numerical improvements, these were not statistically significant.
• The Phase 2b trial was a monotherapy regime, which may have contributed to the lack of statistical significance.

Risks

• The Phase 2b trial did not meet its primary endpoint, indicating that CAN-2409 may not be effective in all prostate cancer risk categories.
• The company is still in the process of seeking regulatory approval for CAN-2409, and there is no guarantee that it will be approved.
• The company's future success depends on the successful commercialization of CAN-2409, which is subject to market acceptance and competition.
• The company's forward-looking statements are subject to risks and uncertainties, including the timing and advancement of development programs and the ability to obtain regulatory approval.

Future Outlook

Candel intends to initiate discussions with the FDA regarding the regulatory pathway for CAN-2409 in intermediate-to-high-risk localized prostate cancer and anticipates submitting a biologics license application in the fourth quarter of 2026.

Management Comments

• Glen Gejerman, M.D., MBA, stated that CAN-2409 has the potential to significantly improve long-term outcomes without adding substantial toxicity to standard of care radiation.
• Paul Peter Tak, M.D., Ph.D., FMedSci, stated that the Phase 3 study validates previous observations of CAN-2409 activity and confirms synergies with radiation therapy.

Industry Context

The announcement is significant as there has not been any new treatment or significant change in the standard of care for localized, non-metastatic prostate cancer for over 20 years, and CAN-2409 has the potential to transform the treatment paradigm in prostate cancer.

Comparison to Industry Standards

• The 14.5% relative improvement in DFS at 54 months is considered clinically meaningful by key opinion leaders, suggesting a significant advancement over existing treatments.
• The hazard ratio of 0.7 for DFS and 0.6 for prostate cancer-specific outcomes in the Phase 3 trial indicates a substantial reduction in the risk of recurrence or death compared to standard of care alone.
• The pathological complete response rate of 80.4% in the CAN-2409 arm is a notable improvement compared to the 63.6% in the control arm, suggesting a strong treatment effect.
• The median overall survival of 20.6 months in NSCLC patients with progressive disease after CAN-2409 treatment exceeds the <12 months reported with standard of care chemotherapy, indicating a potential benefit in this difficult-to-treat population.
• In borderline resectable PDAC patients, the estimated median overall survival of 28.8 months after CAN-2409 treatment compares favorably to the 12.5 months in the control group, suggesting a significant improvement in survival outcomes.

Stakeholder Impact

• Shareholders may view the positive Phase 3 results as a positive development for the company's future prospects.
• Patients with intermediate-to-high risk localized prostate cancer may benefit from a new treatment option that has shown significant improvement in disease-free survival.
• Employees may be encouraged by the positive results and the potential for the company to bring a new treatment to market.
• The company's success may lead to increased revenue and growth, benefiting the company and its stakeholders.

Next Steps

• Candel intends to initiate discussions with the FDA regarding the regulatory pathway for CAN-2409.
• The company anticipates submitting a biologics license application for CAN-2409 in the fourth quarter of 2026.
• The company will present the totality of the data for both studies at upcoming medical conferences.

Key Dates

Keywords

CAN-2409, prostate cancer, immunotherapy, disease-free survival, clinical trial, FDA, biologics license application, radiation therapy, PSA, pathological complete response